What Are the Data Supporting First Line C3 Inhibitor Treatment of PNH?

CME credits: 0.75
Valid until: 22-09-2024
Claim your CME credit at https://reachmd.com/programs/cme/what-are-the-data-supporting-first-line-c3-inhibitor-treatment-of-pnh/16111/

This program provides awareness for practitioners to correctly diagnose Paroxysmal Nocturnal Hematuria (PNH) due to overlap with other diseases, which often causes a delay in diagnosis. The approval of the first complement inhibitor changed the outlook for people with PNH dramatically, yet today, two-thirds to 80% of patients on anti-C5 therapy still suffer from anemia. Approximately a fourth of patients continue to experience breakthrough hemolysis, a loss of disease control that greatly increases the risk of thrombosis. New treatments are tackling those challenges with different approaches to complement inhibition. This program provides an awareness of managing treatment-related adverse events associated with complement inhibitors. In addition, this program focuses on how healthcare providers can best serve their patients by increasing their confidence in knowing how to discern the differences in new therapeutics available and select the optimal first line regimen best suited for their patients with PNH to increase their quality of life.